^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AMG 337

    i
    Other names: AMG 337, AMG337, AMG-337
    Associations

    News

    Trials
    Company:
    Amgen, ImmunityBio
    Drug class:
    c-MET inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost2years
    QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma (clinicaltrials.gov)
    P2, N=8, Terminated, NantPharma, LLC | Active, not recruiting --> Terminated; Prematurely terminated due to lack of therapeutic effect
    Trial termination • Metastases
    |
    EWSR1 (EWS RNA Binding Protein 1) • ATF1 (Activating Transcription Factor 1)
    |
    AMG 337
    3years
    QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, NantPharma, LLC | Recruiting --> Active, not recruiting | N=37 --> 8 | Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Mar 2021 --> Jun 2022
    Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    EWSR1 (EWS RNA Binding Protein 1) • ATF1 (Activating Transcription Factor 1)
    |
    AMG 337
    almost4years
    Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature. (PubMed, PLoS One)
    In vitro treatment of SCNPC patient-derived xenograft (PDX) cells with the MET inhibitor AMG-337 had no impact on cell viability in LuCaP 93 (MET+/RET+) and LuCaP 173.1 (MET-/RET-), whereas cabozantinib decreased cell viability of LuCaP 93, but not LuCaP 173.1...Our data suggest that the most likely mechanism of cabozantinib-mediated tumor growth suppression in SCNPC PDX models is through disruption of the tumor vasculature. Thus, cabozantinib may represent a potential therapy for patients with metastatic disease in tumor phenotypes that have a significant dependence on the tumor vasculature for survival and proliferation.
    Clinical • Journal
    |
    RET (Ret Proto-Oncogene) • AR (Androgen receptor) • CD31 (Platelet and endothelial cell adhesion molecule 1)
    |
    MET expression • AR expression • RET expression
    |
    Cabometyx (cabozantinib tablet) • AMG 337